Immunotherapy Advances is a new Open Access journal brought to you by the British Society for Immunology in collaboration with Oxford University Press and edited by a world leader in the field, Professor Tim Elliott, supported by an Editorial Board of globally-renowned experts.
Scope & mission
Immunotherapy Advances is an Open Access journal from the British Society for Immunology that publishes scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.
Immunotherapy Advances covers the translational pipeline for immunotherapy from discovery research and preclinical animal models through to clinical trials. Experimental medicine and first-in-human clinical studies are encouraged and negative clinical trials are welcomed where they contribute to immune-mechanistic insight. We also recognise the growing importance of interdisciplinary working in this area and encourage studies that are at the interface with engineering, mathematics and computer science, chemistry and the physical sciences.
Topics of interest to the journal include:
- Manipulations of the immune system for the benefit of human and animal health
- Immunotherapeutic interventions (such as small molecules, biotherapeutics and therapeutic vaccines) and their mechanism of action in all disease areas
- Understanding of immunological mechanisms
- Discovery research through to clinical trials
- Interdisciplinary research with physical sciences, maths and engineering
BSI member discount
As Immunotherapy Advances is an official journal from the British Society for Immunology we are pleased to offer a 20% discount on publication fees for BSI members. All BSI members are eligible for a discounted Article Processing Charge (APC) of £1,600. Find out more.
Find out more
- Visit the official Immunotherapy Advances website
- Connect with @IMTadvances on Twitter
- Be one of the first authors published in Immunotherapy Advances - - submit your work.
- Keep up to date by signing up to receive email alerts when content is published*
Editor-in-Chief: Tim Elliott, FRSB, FMedSci
Professor of Experimental Oncology, Faculty of Medicine, University of Southampton.
Professor Elliott received a first in Biochemistry from the University of Oxford, a PhD from the University of Southampton, and went on to complete his postdoctoral training at the Massachusetts Institute of Technology. Professor Elliott held a lectureship and later a professorship in immunology at the Weatherall Institute for Molecular Medicine and Balliol College, University of Oxford before being appointed to the Chair of Experimental Oncology at the University of Southampton. He held a number of senior positions there including Associate Dean for the Faculty of Medicine and Deputy Director of the Institute for Life Sciences and in 2016 established the UK’s first dedicated Centre For Cancer Immunology, becoming its first Director. He was appointed to the Kidani Chair for Immuno-oncology at the University of Oxford in 2021, and is a visiting Professor at the University of Southampton.
His research focuses on antigen processing and presentation, which is how the body prepares viruses and cancer cells for recognition (and eventual destruction) by the immune system, and is fundamental for the development of immunotherapies. Over his career he has made significant contributions to understanding the biochemistry and immunostimulatory properties of MHC class I molecules and their role in generating cytotoxic T cell responses to infections and cancer.
His studies combine approaches from the physical sciences, structural biology, mathematics and computational chemistry, with cellular and organism level immunology: enabling him to model immune pathways to predict the outcome of responses to infection, cancer and vaccines.
Asia: Professor Tao Dong, Oxford University, Oxford, UK
Professor of Immunology, Program Leader at the MRC Human Immunology Unit, Founding Director of CAMS-Oxford joint International Centre for Translational Immunology, and Founding Director of Chinese Academy of Medical Sciences Oxford Institute, University of Oxford.
Professor Dong has held the post Professor of Immunology in the MRC Human Immunology Unit at Oxford University since 2014 and is a Senior Fellow at University College Oxford. She has served as a member of the UK Medical Research Council Infection and Immunity board between 2016-2020. She is founding director of CAMS Oxford joint International Centre for Translational Immunology since 2013, and founding director (Oxford) of CAMS Oxford Institute based in Nuffield Department of Medicine, Oxford University since 2019.
Professor Dong originally gained a BSc degree in Physiology from Fudan University, Shanghai, China in 1987. She moved to Oxford University in 1993 where she received a DPhil degree in Immunology in 1998 for work carried out under the supervision of Professors Sarah Rowland-Jones and Sir Andrew McMichael on qualitative changes in HIV-specific cytotoxic T cells associated with HIV disease progression. During her postdoctoral training, where she continued to study immune responses to HIV, Professor Dong expanded her research interests to include work on influenza virus infection, which led her to start her own independent research group. In 2010 she became the Head of the human anti-viral and anti-cancer cytotoxic T cell laboratory and a Program Leader in the MRC Human Immunology Unit at Oxford University. Since 2013, the main focus of Professor Dong's research has switched from virus infections to cancer, with a central goal being to identify determinants of the ability of human tumour-specific cytotoxic T cells to control human tumour development and metastasis.
Europe: Associate Professor Marianne Boes, University Medical Center Utrecht, Utrecht, Netherlands
Africa: Professor Stefan Barth, University of Cape Town, Cape Town, South Africa
South America: Professor Adriana Bonomo, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Australasia: Associate Professor Menno van Zelm, Monash University, Melbourne, Australia
North America: Dr Stephanie K Dougan, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
*The email alerting service is from our publisher, Oxford University Press.